

# Selected topics in Clinical Immunology

---

## Psoriasis

-

## Immunology and Pathogenesis

---

Christoph Schlapbach

MD, PhD

Department of Dermatology

University of Bern

Switzerland

[christoph.schlapbach@insel.ch](mailto:christoph.schlapbach@insel.ch)


*b*  
**UNIVERSITÄT  
BERN**

 **INSELSPITAL**  
UNIVERSITÄTSSPITAL BERN  
HOPITAL UNIVERSITAIRE DE BERNE  
BERN UNIVERSITY HOSPITAL  
BERN, SWITZERLAND

# Definition of Psoriasis



Genetics



Immune system  
Innate IS  
Adaptive IS



Environmental  
factors



Chronic - relapsing



Common disease


Skin  
manifestations



Joint  
manifestations



Comorbidity  
Quality of life  
Metabol. disease






# Prevalence

Prevalence world wide: 2%

North America / Europe: up to 4%

Lapps/Africa/Asia: 0.4 – 0.7%



Prevalence **Asthma** world wide: 4.5% - 14%

Prevalence **Rheumatoid Arthritis** world wide: 0.4 – 1.3%



# Epidemiology: Good and bad news



80% mild psoriasis  
(topical treatment only)

5 - 20% psoriasis arthritis



75% onset before 40 years of age

80% psoriasis of the scalp (most frequent localisation)

nail changes: 50% at diagnosis, 70% life time

# Clinical face of psoriasis




# Clinical face of psoriasis



# Clinical face of psoriasis



# Clinical face of psoriasis





# Pathological hallmarks of psoriasis

Abnormal differentiation and hyperproliferation of keratinocytes




Infiltration of inflammatory cells  
Increased dermal blood vessels


# Normal & psoriatic skin



# The skin immune system




# Immuno-pathogenesis of psoriasis



# Trigger factors

Trauma

Koebner phenomenon



Infections

Streptococci

HIV



Drugs



Behavioural factors




Occupational factors



# Genetics & Pathogenesis



Genetics



Immune system  
Innate IS  
Adaptive IS



Environmental  
factors


Skin  
manifestations



Joint  
manifestations



Comorbidity  
Quality of life  
Metabol. disease



# Genetics of psoriasis




## Population studies



1<sup>st</sup>/2<sup>nd</sup> degree relatives: Higher incidence of psoriasis



Concordance rate in monozygotic twins =  
3-times higher than in discordant twins



Type I: positive family history – more severe course  
Type II: negative family history – milder course


# Genetics of psoriasis



## Genetic studies



>40 susceptibility loci are associated with psoriasis





Candidate genes suggest key role for

- adaptive immunity
- innate immunity
- skin barrier functions

# Genetics of psoriasis


## PSORS1




# Genetics of psoriasis

Gene / locus	Chromosomal location	Odds ratio
PSORS1	6p	6.4
PSORS2	17q	-
IL12B	5q	1.4
IL23R	1p	2.0

# T helper ( $T_H$ ) cells





# T helper cell subsets



# Role of T cells in psoriasis

## Xenotransplantation models

1. Non-lesional human skin from healthy or psoriasis donor
2. Engrafted onto immuno-compromised mice
3. Spontaneous development of psoriatic phenotype (psoriasis donors but not healthy donors)
4. Blocking of T cells lead to inhibition of psoriasis development



# Role of T cells in psoriasis

## Infiltrate:

- memory-effector T cells

CD4 ↔ DC, macrophages



CD8 ↔ keratinocytes

- T cells are activated

- CD69, CD25, HLA-DR

- clonal T cell expansions

- antigen-specific stimulation




# The 1 million dollar question in psoriasis




What is the antigen ?

# Putative antigen(s)?

- $\beta$ -haemolytic streptococci can trigger psoriasis




- T cells cross-react with epitops which are common to streptococcal M protein and keratins



# Innate immunity is critical for T cell activation

Signal 2:

- Co-stimulatory molecules
- Adhesion molecules



Signal 1: Antigen

T cell

LFA1

ICAM1

LFA1

CD2

CD28

CD80

CD80


Signal 3:

- Cytokines (IL-2, IL-12, IL-23,...)


# Innate immunity in psoriasis

Psoriatic skin is highly infiltrated by dendritic cells (DC)

- plasmacytoid DC (BDCA-2)
- myeloid DC (CD11c, BDCA-1<sup>-</sup>)




# Activation of DC and production of cytokines



# Key cytokines in psoriasis: IFN- $\alpha$

## Xenotransplantation models:

- Psoriasis is inhibited by anti-BDCA-2
- fully restored by addition of human IFN- $\alpha$



Day 0



Anti-BDCA-2




Anti-BDCA-2 + IFN  $\alpha$




Day 35

# Key cytokines in psoriasis: TNF- $\alpha$

- Enhanced expression in
  - skin
  - joints
  - serum (correlates with activity)
- Produced by multiple cells
  - DC, macrophages
  - T cells
  - mast cells
  - keratinocytes, endothelial cells



# Key cytokines in psoriasis: TNF- $\alpha$




# Modulation of key cytokines

## TNF Antagonists

Etanercept

Adalimumab

Infliximab



# Infliximab (anti-TNF- $\alpha$ Antibody)




before Infliximab




on Infliximab since 3 years

# Key cytokines in psoriasis: IL-12 and IL-23


IL-12



IL-23




# T helper cell subsets




# IL-12 & IL-23: heterodimers with common p40 subunit


- IL-12 and IL-23 bind to specific receptors on T cells and natural killer cells
- Strongly influence T cell differentiation and activation



# Th1 cytokines: inflammatory processes in psoriasis




# Th17 cytokines: inflammation and keratinocyte hyperplasia



# Modulation of key cytokines

- Anti-IL-12/IL-23 p40

Ustekinumab



# Ustekinumab (anti-p40-Ab)



Before Ustekinumab



week 12




week 52

# Summary: Key steps in the immunopathogenesis


## Activation of DC and T cells

- Stimulation of keratinocytes
- Neovascularisation
- Recruitment of further leucocytes

## Perpetuation of inflammation



# Immunogenetics of psoriasis



# Thank you for your attention

